SCHEMBL6777988

SCHEMBL6777988

COc1cc(OC)cc(C(CC(=O)O)NC(=O)CNC(=O)c2cccc(NC(=N)N)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 3/20 0.49
ITGB3 P05106 10/20 0.47
ITGAV P06756 7/20 0.47
ITGB1 P05556 5/20 0.47
ITGA5 P08648 5/20 0.47
ITGB5 P18084 3/20 0.47
ITGB6 P18564 3/20 0.47
ITGB8 P26012 3/20 0.47
ITGA8 P53708 3/20 0.47
ITGA2B P08514 3/20 0.46
F2 P00734 1/20 0.45
F7 P08709 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ITGA2 P17301 1/20 0.42
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777808 0.91 ITGB3 (0.46) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6780563 0.91 ITGB3 (0.46) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7338356 0.90 SMN1; SMN2 (0.44) GPR139F2F7MEN1KMT2A
SCHEMBL6773834 0.88 ITGB3 (0.51) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL242674 0.88 ITGB3 (0.55) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6779037 0.87 MAPK1 (0.48) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL7343510 0.86 GPR139 (0.51) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6773401 0.86 ITGB3 (0.50) GPR139ITGB3ITGAVITGB1ITGA5
SCHEMBL6779336 0.86 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5ITGB5
SCHEMBL244261 0.86 ITGB3 (0.50) GPR139ITGB3ITGAVITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed